Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.58 +2.3%	$5.02	$3.42 ▼ $7.20	$255.21M	1.75	1.58 million shs	708,073 shs
GANX Gain Therapeutics	$1.69 +3.4%	$1.86	$0.89 ▼ $3.19	$50.61M	0.12	297,081 shs	244,351 shs
NGNE Neurogene	$20.05 +1.5%	$17.77	$6.88 ▼ $74.49	$286.52M	1.51	251,325 shs	75,550 shs
TVRD Tvardi Therapeutics	$22.46 +4.7%	$0.00	$8.13 ▼ $34.31	$210.25M	0.2	96,313 shs	19,658 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+10.24%	-17.86%	+14.09%	-6.63%
GANX Gain Therapeutics	0.00%	-14.21%	-15.08%	+2.42%	+45.69%
NGNE Neurogene	0.00%	+24.04%	-7.50%	+128.04%	-44.29%
TVRD Tvardi Therapeutics	0.00%	-8.74%	-7.72%	+2,245,999,900.00%	+2,245,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.1881 of 5 stars	0.0	1.0	0.0	0.0	1.6	0.8	0.6
GANX Gain Therapeutics	3.1149 of 5 stars	3.6	5.0	0.0	0.0	2.8	0.0	0.6
NGNE Neurogene	3.8091 of 5 stars	4.4	3.0	0.0	0.0	1.7	2.5	1.3
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.67	Strong Buy	N/A	N/A
GANX Gain Therapeutics	3.17	Buy	$8.20	385.21% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	130.32% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$71.50	218.34% Upside

Current Analyst Ratings Breakdown

Latest GANX, ACB, NGNE, and TVRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$246.72M	1.04	$0.62 per share	7.43	$7.78 per share	0.59
GANX Gain Therapeutics	$50K	1,012.31	N/A	N/A	$0.28 per share	6.04
NGNE Neurogene	$930K	307.36	N/A	N/A	$20.89 per share	0.96
TVRD Tvardi Therapeutics	$7.14M	29.44	N/A	N/A	($3.02) per share	-7.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	$1.63M	$0.11	41.59	10.40	N/A	1.32%	0.13%	0.10%	8/6/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/6/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest GANX, ACB, NGNE, and TVRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/18/2025	Q4 2025	ACB Aurora Cannabis	$0.11	$0.07	-$0.04	-$0.24	$88.85 million	$63.34 million
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.13	4.31	2.16
GANX Gain Therapeutics	0.05	2.22	2.22
NGNE Neurogene	N/A	21.03	21.03
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
GANX Gain Therapeutics	11.97%
NGNE Neurogene	52.37%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
GANX Gain Therapeutics	7.18%
NGNE Neurogene	11.64%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,130	56.21 million	56.21 million	Optionable
GANX Gain Therapeutics	20	29.95 million	27.80 million	Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

GANX, ACB, NGNE, and TVRD Headlines

Recent News About These Companies

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler

June 12, 2025 | marketbeat.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, ACB, NGNE, and TVRD Company Descriptions

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$4.57 -0.01 (-0.22%)

As of 07/3/2025 04:53 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Gain Therapeutics NASDAQ:GANX

$1.69 +0.06 (+3.36%)

Closing price 07/3/2025 03:32 PM Eastern

Extended Trading

$1.70 +0.01 (+0.59%)

As of 07/3/2025 04:49 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Neurogene NASDAQ:NGNE

$20.05 +0.30 (+1.49%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$20.00 -0.05 (-0.25%)

As of 07/3/2025 04:15 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Tvardi Therapeutics NASDAQ:TVRD

$22.46 +1.01 (+4.71%)

As of 07/3/2025 01:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time